Utilising AI and deep learning from millions of patients, to identify potential risks and diseases
AI Technology Fundas Camera for Ophthalmologists Endocrinologists Optometrists Diabetologists Insurers & Payors Physicians & GPs
The global OCT and Fundus Camera market is poised for significant growth during the forecast period, registering a robust compound […]
Diabetic retinopathy (DR) is one of the leading causes of blindness among adults worldwide. The condition arises when high blood […]
The eyes are often referred to as the windows to the soul, but they are also critical windows to overall […]
Introducing UK AI Medical®
The UK AI Medical Eye Screening System from AirDoc is the most validated AI for detecting diabetic retinopathy, with over 30 million scans. It provides accurate, instant reports and detects 35+ diseases and health risks.
Introducing AirDoc AI technology
Airdoc’s AI technology achieved 96% sensitivity and 88% specificity for more-than-mild DR, and 97% sensitivity and 90% specificity for vision-threatening DR, with a 98% imageability rate, meeting all primary endpoints (p<0.0001).
Why use AirDoc technology for Retina scanning;
✔ Accurate analysis using over 30 million global patient data and scan results
✔ CE Marking accreditation and UKCA approval pending (Q1-2025)
✔ User-friendly: no specialized training needed to generate AI reports
✔ Detects 35 diseases and multiple health risks
✔ Microsoft-backed software with strong cybersecurity to protect data integrity
Elevate Patient Care with the Confidence of AI Eye Screening
A renowned expert in ophthalmology and Director of Retina Service shared groundbreaking clinical trial study results conducted by Airdoc. These results were unveiled at a prestigious international conference, showcasing significant advancements and insights in the field of eye care and medical imaging. Additionally, the expert provided an in-depth analysis of the study’s findings through a comprehensive multi-part interview series with MD Magazine. These discussions explored the potential implications of the study on future medical practices and patient outcomes. Click on the video to watch the full interview and gain a deeper understanding of this impactful research
Undiagnosed Diabetic Retinopathy is a Thing of the Past
AI Eye Screening with Airdoc helps eliminate the biggest obstacle to annual DR screening and diagnosis: patient compliance.
Airdoc enables any physician to identify patients with vision-threatening retinopathy in-clinic, in real-time, allowing for immediate referrals to an eyecare specialist for treatment to preserve their sight.
Test and Give Results to Patients in the Same Appointment
Whether you work with diabetes patients as a general practitioner, endocrinologist, diabetologist, ophthalmologist, or optometrist, Airdoc enables fast, reliable, and accurate diabetic retinopathy screening for your patients.
Discover how easy it is to integrate Airdoc into your practice.
Want to try our AI retina scanner
UK AI Medical can be seamlessly integrated with your clinical workflow to enable automated DR screening. Click to get started.
Our Product Suite
Products under development. Click here to know more.
Auxiliary Diagnosis
of Diabetic Retinopathy
Accurately Track
Retinopathy Progression
The Airdoc AI
Medical Retina Detection
For AMD Detection
UK AI Medical TM
Glaucoma
for Glaucoma Detection
” UK AI Limited lesion detection and DR screening will allow us to better monitor our teleretinal patients at a lower cost in the under-resourced setting in which we care for Los Angeles’s most disadvantaged patients
“EyeArt’s automatic lesion detection and DR screening will allow us to better monitor our teleretinal patients at a lower cost in the under-resourced setting in which we care for Los Angeles’s most disadvantaged patients
“EyeArt’s automatic lesion detection and DR screening will allow us to better monitor our teleretinal patients at a lower cost in the under-resourced setting in which we care for Los Angeles’s most disadvantaged patients
“EyeArt’s automatic lesion detection and DR screening will allow us to better monitor our teleretinal patients at a lower cost in the under-resourced setting in which we care for Los Angeles’s most disadvantaged patients
“EyeArt’s automatic lesion detection and DR screening will allow us to better monitor our teleretinal patients at a lower cost in the under-resourced setting in which we care for Los Angeles’s most disadvantaged patients
UK AI Medical Limited in the news
